

Press Release

Korea Investment Management Launches KIM ACE Global Big Pharma ETF, Tracking the Solactive Global Big Pharma Index

20th November 2024

FRANKFURT AM MAIN – Solactive is pleased to expand its collaboration with Korea Investment Management (KIM), launching the Solactive Global Big Pharma Index that applies market data expert Evaluate Pharma's robust data resources. This index offers investors strategic exposure to the top performing pharmaceutical and biotechnology companies globally, providing clients targeted exposure to the healthcare sector. Evaluate as a data solutions and analytics company, provides over 20 years of trusted pharmaceutical data solutions and expertise to empower confident decision-making. Vast proprietary sources are distilled into clear intelligence addressing strategic challenges in development and commercialization.

With rapid advancements in medical research, technology, and an increasing global demand for healthcare, the pharmaceutical industry is expected to experience substantial growth in the following years. The aging population and the prevalence of chronic diseases continue to drive the demand for prescription drugs and other medical treatments. According to research, the sector's revenue is forecast to grow at an annual rate of around 7.7% until 2030, reaching a predicted sales volume of \$1.7 trillion by the end of the decade¹.

The [Solactive Global Big Pharma Index](#) comprises 15 top companies from the pharmaceuticals and biotechnology sectors listed on the New York Stock Exchange, NASDAQ, or the SIX Swiss Exchange. The index focuses specifically on companies with at least one "Big Pharma Drug", defined as a major pharmaceutical product generating substantial sales. Using revenue and growth data provided by Evaluate Ltd., potential constituents are selected based on their current free-float market capitalization along with projected revenue growth rate. The index constituents are weighted according to their adjusted free-float market capitalization with a maximum individual weight capped at 20%.

The ETF is listed on 19th November on the Korean Stock Exchange with the ticker code "497510.KS".

Timo Pfeiffer, Chief Markets Officer at Solactive, comments: *"We are delighted to partner with KIM to bring this inventive index to the market. The Solactive Global Big Pharma Index provides investors an attractive*

¹ [World Preview 2024: Pharma's Growth Boost](#)

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Michelle Zhang / Katerina Xagorari
PR & Communications
+49 (69) 719 160-311
press@solactive.com

investment opportunity to capture such growth in the biopharma industry, in which its significance grows along with the rising global demand for healthcare products and services."

Yongsoo Nam, Managing Director and Head of ETF Management at Korea Investment Management, comments:
"We're excited to launch our product in collaboration with Solactive and Evaluate. Advances in AI technology are expected to drive significant growth in the pharmaceutical and biotech industries. Big pharmaceutical companies, with its strong capitalization and economic moats (such as brand power, R&D capabilities, and blockbuster drugs), will be the biggest beneficiary of this growth and will continue to lead the market."

The KIMACE Global Big Pharma ETF invests in a market-representative selection of big pharmaceutical companies, focusing on drug revenue growth while strategically accounting for patent expiration risks and drug development events. We aim to position this ETF as a leading product in the pharmaceutical biotechnology market."

Thomas Halliday, General Manager at Norstella's Strategic Intelligence Portfolio (inclusive of Evaluate Pharma), comments:
"We are pleased to partner with KIM and Solactive to bring this inventive index to the market. This new index will enable the investment and trading community to benchmark key areas of growth, emerging pharmaceutical technologies, and clinical innovations that will enable them to make effective investment decisions. 2025 presents a promising opportunity for the biopharma industry."

For more information, please visit:

<http://www.solactive.com>

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Michelle Zhang / Katerina Xagorari
PR & Communications
+49 (69) 719 160-311
press@solactive.com

Note to editors

About Solactive

Solactive is a leading provider of indexing, benchmarking, and calculation solutions for the global investment and trading community. Headquartered in Frankfurt and, with offices in Hong Kong, Toronto, Berlin, Dresden, and Amsterdam, we innovate and disrupt the status quo as the partner of choice for our clients.

The unique blend of our 300 staff's expertise in data, data science, financial markets, and technology enables our clients' continued success through the delivery of a superior experience, unique customization capabilities, and the best value for money available in the industry. With more than 30,000 indices calculated daily, we offer a full suite of solutions, including market-leading ESG and thematic indices.

As at January 2024, Solactive served approximately 500 clients across the world, with approximately US\$300 billion invested in products linked to our indices. Solactive is registered with ESMA as a benchmark administrator and is supervised by the BaFin.

Disclaimer

The information in this document does not constitute tax, legal or investment advice and is not intended as a recommendation for buying or selling securities. Solactive AG and all other companies mentioned in this document are not responsible for the consequences of reliance upon any opinion or statement contained herein or for any omission.

Solactive AG, Platz der Einheit 1, 60327 Frankfurt am Main, Germany. Registered Office: Frankfurt am Main, Registration Court: Amtsgericht Frankfurt am Main, HRB: 79986, USt-IdNr.: DE 255 598 976. Management Board: Steffen Scheuble, Timo Pfeiffer, and Nicolas Bös, Head of Supervisory Board: Dr Felix Mühlhäuser.

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Michelle Zhang / Katerina Xagorari
PR & Communications
+49 (69) 719 160-311
press@solactive.com